Form 4: C4 Therapeutics CEO Andrew Hirsch Reports Stock Transactions
SEC Form 4 Filing
C4 Therapeutics CEO Andrew Hirsch reports the vesting and settlement of performance restricted stock units (PRSUs) and shares withheld for tax obligations.
Summary
- On November 7, 2024, Andrew Hirsch, the President & CEO and a director of C4 Therapeutics, Inc. [CCCC], reported transactions involving the company's common stock and performance restricted stock units (PRSUs).
- Hirsch acquired 12,500 shares of common stock through the vesting of PRSUs.
- 5,550 shares were withheld by C4 Therapeutics to satisfy tax withholding obligations related to the vesting and settlement of the PRSUs at a price of $6.04.
- Following these transactions, Hirsch directly owns 221,862 shares of C4 Therapeutics common stock and 35,000 performance restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider transactions, which is neither inherently positive nor negative. It's a neutral disclosure.
Industry Context
This is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
- The tax withholding impacts the company's cash flow, although likely immaterially.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of stock transactions (vesting of PRSUs and tax withholding). |
| 02/28/2025 | Expiration date of Performance Restricted Stock Units. |
| 11/12/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.